Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 19;13(2):163. doi: 10.1038/s41419-022-04569-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — A A panel of 22 cancer cell lines of different origins were treated with increasing concentrations of Palbo, Ribo and Abema. B Crystal violet staining showing the 8 cancer cell lines that responded in a statistically significant (p < 0.05) and dose-dependent manner to more than 2 inhibitors. Representative experiment is shown. C Venn diagram shows that SKMEL28 (melanoma), MCF7 (breast cancer), ACHN (renal adenocarcinoma), HT-29 (colon) and SNU-387 (liver) cancer cell lines responded to two or more CDK4/6/ inhibitors (p < 0.05) in a Secondary Screen and were selected for further validation. D Heat map showing F9 mRNA expression in the indicated cancer cells after treatment with different CDK4/6 inhibitors. The map represents the mean of 3–5 independent replicates. E ACHN control or expressing shF9#4 stained with crystal violet after 20 days treatment with Palbo show a partial proliferation bypass. See also Fig. S5.